Previous 10 | Next 10 |
Shares of mental health biopharma Atai Life Sciences N.V. have fallen some two-thirds from their June 2021 IPO pricing as the biotech market continues to crater. The company’s approach of identifying (in many instances psychedelic) compounds that have been tested in previous hu...
Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression London, UK – 23 May 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company de...
When looking at the data coming out of psychedelics research, there is tantalizing evidence that the promise of psychedelics is becoming more of a reality every day. Companies and organizations such as Compass Pathways NASDAQ: (CMPS) the Multidisciplinary A...
German clinical-stage biopharmaceutical company Atai Life Sciences (NASDAQ:ATAI) is trading higher on Monday in reaction to the company’s 1Q 2022 results. The U.K.-based biotech COMPASS Pathways (CMPS), in which it holds an ownership stake, is also rising in solidarity. Atai&...
Recently released findings from a study show that the psilocybin therapy developed by Compass Pathways PLC (NASDAQ: CMPS) may be used to treat anorexia . The therapy in question, COMP 360, was primarily developed to treat depression. Anorexia or anorexia nervosa is an eating disorder in w...
LONDON, May 12, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming events as follows: Citi...
Compass Pathways (NASDAQ:CMPS) stock rose ~10% on May 10 after the company reported its Q1 results. Net loss widened to -$21.17M, compared to -$12.72M in Q1 2021. GAAP EPS of -$0.50 beat analysts' estimates by $0.19. "COMPASS made great progress this quarter including a productive end-of...
Image source: The Motley Fool. COMPASS Pathways plc (NASDAQ: CMPS) Q1 2022 Earnings Call May 10, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: COMPASS Pathways plc (CMPS) Q1 2022 Earnings Call Transcript
COMPASS Pathways plc (CMPS) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET Company Participants Steven Schultz - SVP, IR George Goldsmith - Chairman & CEO Guy Goodwin - Chief Medical Officer Mike Falvey - CFO Conference Call Participants Josh Schimmer - Evercore ISI Charles Dunc...
During an earnings and clinical program update conference call today, George Goldsmith, founder and CEO of Compass Pathways (NASDAQ: CMPS), along with Dr. Guy Goodwin, chief medical officer and Mark Falvey, chief financial officer, discussed developments related to COMP360, upda...
News, Short Squeeze, Breakout and More Instantly...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...
New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes. Researchers have observed that in animals, psilocyb...